Dr. Shin Kaneko, Founder/Director of Thyas and Professor/Deputy Director at the Center for iPS Cell Research and Application, Kyoto University (CiRA), and his colleagues have reported that “Genetic modifications boosting CAR signaling improve the therapeutic efficacy of iPSC-derived CAR-T cells against solid tumors”. The research finding was published in Nature Biomedical Engineering on Dec. 13th, 2022 (JST).